On the Couch with Nathan Smith (Neuroscientific): Inside the StemSmart Strategy for Crohn's

Welcome to the latest episode of On the Couch.

In this episode, Henry Jennings from Marcus Today sits down with Nathan Smith, CEO of Neuroscientific Biopharmaceuticals, to unpack how a differentiated mesenchymal stem cell therapy is progressing from acquisition to patient impact in refractory Crohn's disease.

With promising real-world data via special access programs, a clear regulatory path, and lean execution, the company is preparing for a focused Phase 2 push in 2026.

Topics covered in this episode:

• What the StemSmart MSC platform is – and why differentiation matters
• Special access program results in fistulising Crohn's
• Prior early-phase data and how it informs trial design
• Market size for refractory Crohn's and broader inflammatory targets
• Regulatory steps, including pre-IND and TGA interactions
• Manufacturing tech transfer with QGen and licensure plans
• 2026 milestones across CRO onboarding, trial initiation, and IP expansion
• Cash runway to trial start and approach to raising capital
• Competitive landscape and lessons from Mesoblast's US approval
• A CEO's take on what actually drives market value

—

Marcus Today – Daily Market Insights

Marcus Today provides clear, practical commentary for self-directed investors – covering markets, portfolios, education, and decision-making without the noise.

If you'd like to go further:

Start a free 14-day trial of Marcus Today
http://bit.ly/mt-trial-podcast

Join Marcus Today
Use code MTPODCAST for 10% off
http://bit.ly/mt-join-podcast-offer

MT20 – Managed ETF Portfolio
A professionally managed portfolio run by Marcus Padley and the team, using ASX-listed ETFs with active market timing.
http://bit.ly/mt20-podcast

Principles – How We Think About Investing
A short video series on timing, behaviour, and decision-making. No stock tips.
http://bit.ly/mt-principles-podcast

—

Disclaimer
This podcast is general information only and does not consider your personal circumstances. It is not personal financial advice.